Platform
Home
Screener
Copilot
AskEdgar Studio
New
Back
Lisata Therapeutics, Inc.
LSTA · SEC Filings
website
21
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bring...
Price
1.12
Market Cap
12.1 M
Float
8.6 M
Country
US
Sector
Healthcare
Exchange
NASDAQ
Overview
Filings
Insights
Dilution
News
Transcripts
Search in Documents
Open in Studio
Studio
Login
Ask about LSTA
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
All
Chronological
Financials
Registrations
Prospectus
News
Proxies
Ownerships
Other
Lisata Therapeutics, Inc.
LSTA · SEC Filings
8.6 M
Float
1.12
Price
12.1 M
Market Cap
Financials
TYPE
HEADLINE
FILED AT
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 6, 2026
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
May 11, 2026
10-K/A
Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
Apr 28, 2026
10-K
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Mar 12, 2026
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 6, 2025
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 7, 2025
News
TYPE
HEADLINE
FILED AT
8-K
NEW
Lisata Therapeutics Announces Voting Results from 2026 Annual Meeting and Adjournment of Conversion Proposal
Nov 9, 2026
8-K
Lisata Therapeutics Appoints Jeff Farrow to Board of Directors and Audit Committee
Oct 14, 2026
8-K
Lisata Therapeutics Acquires Marea Therapeutics and Announces $225 Million Private Placement
Sep 17, 2026
8-K
Lisata Therapeutics Announces 72% Workforce Reduction and Legal Action Against Kuva Labs
Aug 4, 2026
8-K
Lisata Therapeutics Terminates Merger Agreement with Kuva Labs
Jul 24, 2026
8-K
Lisata Therapeutics Extends Merger Agreement Outside Date
Jul 17, 2026
Prospectus
TYPE
HEADLINE
FILED AT
424B5
ATM | Offering amount: $9,855,890 | Amount sold to date: $0 | Float: 7,991,264
Aug 21, 2024
424B5
ATM | Offering amount: $17,698,943 | Amount sold to date: $0 | Float: 6,555,164
Sep 26, 2022
425
Registration
Sep 2, 2022
425
Registration
Aug 15, 2022
425
Registration
Aug 10, 2022
424B3
UPDATED
Jul 29, 2022
Registrations
TYPE
HEADLINE
FILED AT
D
Form D - Notice of Exempt Offering of Securities - Item 06b
Oct 2, 2026
SC TO-T/A
Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
Jul 28, 2026
SC TO-T/A
Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
Jul 17, 2026
SC TO-T/A
Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
Jul 10, 2026
SC TO-T
Form SC TO-T - Tender offer statement by Third Party
Jun 10, 2026
SC TO-C
Form SC TO-C - Written communication relating to an issuer or third party
Jun 1, 2026
Proxies
TYPE
HEADLINE
FILED AT
DEFA14A
NEW
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Nov 9, 2026
DEF 14A
Form DEF 14A - Other definitive proxy statements
Oct 19, 2026
PRE 14A
Form PRE 14A - Other preliminary proxy statements
Oct 7, 2026
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 25, 2025
DEF 14A
Form DEF 14A - Other definitive proxy statements
Apr 25, 2025
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 29, 2024
Ownerships
TYPE
HEADLINE
FILED AT
3
Farrow Jeffrey S (Reporting)
Oct 15, 2026
3
LOVE TED W (Reporting)
Sep 28, 2026
3
Lehrer-Graiwer Joshua (Reporting)
Sep 28, 2026
SCHEDULE 13G
Branham Justin Earl (Filed by)
Aug 26, 2026
4
Mazzo David J (Reporting)
Jan 13, 2026
4
Nisco James (Reporting)
Jan 13, 2026
Chronological
TYPE
HEADLINE
FILED AT
Other
TYPE
HEADLINE
FILED AT
EFFECT
Form EFFECT - Notice of Effectiveness
May 10, 2024
CORRESP
Form CORRESP - Correspondence
May 7, 2024
LETTER
Form UPLOAD - SEC-generated letter
May 6, 2024
EFFECT
Form EFFECT - Notice of Effectiveness
Jul 29, 2022
CORRESP
Form CORRESP - Correspondence
Jul 26, 2022
EFFECT
Form EFFECT - Notice of Effectiveness
May 5, 2021
